GSK PLC-SPON ADR (GSK)
US37733W2044 - ADR
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 748.00M | 879.00M | 1.43B | 1.76B | 795.00M | |||
| Cash Equivalents | 2.00B | 3.72B | 4.27B | 6.29B | 4.71B | |||
| Marketable Securities | 2.25B | 7.00B | 2.91B | 4.61B | 3.99B | |||
| Receivables | 7.40B | 7.12B | 8.03B | 7.26B | 7.15B | |||
| Inventories | 5.50B | 5.15B | 5.78B | 6.00B | 5.95B | |||
| Other Current Assets | 751.00M | 631.00M | 525.00M | 617.00M | 1.61B | |||
| Total Current Assets | 18.64B | 20.77B | 18.67B | 20.25B | 19.49B | |||
| Non-Current Assets | ||||||||
| PPE Net | 9.96B | 9.62B | 10.67B | 11.01B | 11.31B | |||
| Investments And Advances | 1.19B | 1.54B | 2.21B | 3.42B | 2.15B | |||
| Goodwill | 6.81B | 7.05B | 10.55B | 10.60B | 10.56B | |||
| Intangibles | 14.77B | 14.32B | 30.08B | 29.82B | 30.95B | |||
| Other Non-Current Assets | 6.68B | 5.89B | 5.98B | 4.47B | 4.33B | |||
| Total Non-Current Assets | 40.36B | 39.38B | 60.43B | 60.18B | 60.20B | |||
| TOTAL ASSETS | 59.01B | 60.15B | 79.10B | 80.43B | 79.69B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 1.01B | 1.64B | 802.00M | 1.15B | 5.02B | |||
| Current Portion Of LT Debt. | 1.81B | 2.31B | 2.80B | 2.58B | 1.90B | |||
| Accrued Expenses | 10.71B | 10.59B | 11.19B | 9.75B | 9.11B | |||
| Accounts Payable | 3.72B | 3.87B | 4.54B | 4.36B | 4.14B | |||
| Other Current Liabilities | 3.83B | 4.41B | 4.35B | 4.31B | 3.88B | |||
| Total Current Liabilities | 21.07B | 22.81B | 23.67B | 22.15B | 24.05B | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 15.21B | 17.04B | 20.57B | 23.43B | 23.59B | |||
| Deferred Taxes/Income | 311.00M | 289.00M | 3.56B | 3.60B | 3.81B | |||
| Other Non-Current Liabilities | 9.63B | 9.92B | 9.96B | 10.45B | 9.88B | |||
| Total Non-Current Liabilities | 24.59B | 26.74B | 40.38B | 43.70B | 44.24B | |||
| TOTAL LIABILITIES | 45.66B | 49.55B | 64.05B | 65.84B | 68.29B | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | 9.37B | 6.49B | 10.07B | 8.88B | 6.66B | |||
| Additional Paid In Capital | 3.45B | 3.44B | 3.30B | 3.28B | 3.17B | |||
| Minority Interest | -932.00M | -1.17B | 5.58B | 5.58B | 6.33B | |||
| Common Shares | 1.35B | 1.35B | 1.35B | 1.35B | 1.35B | |||
| Other Shareholders' Equity | -310.00M | -373.00M | -49.00M | -226.00M | -183.00M | |||
| Shares Outstanding | 2.01B | 2.00B | 2.00B | 2.00B | 1.96B | |||
| Tangible Book Value per Share | -2.03 | -2.67 | -6.35 | -6.42 | -7.60 | |||
| Total Shareholders' Equity | 13.35B | 10.60B | 15.05B | 14.59B | 11.40B | |||
| TOTAL LIABILITIES AND EQUITY | 59.01B | 60.15B | 79.10B | 80.43B | 79.69B | |||
| Statistics | ||||||||
| Debt/Equity | 1.21 | 1.76 | 1.42 | 1.68 | 2.51 | |||
| Current Ratio | 0.88 | 0.91 | 0.79 | 0.91 | 0.81 | |||
| Return On Assets (ROA) | 8.35% | 24.87% | 5.54% | 7.15% | 5.83% | |||
| Return On Equity (ROE) | 36.92% | 141.12% | 29.13% | 39.41% | 40.73% | |||
| Return On Invested Capital (ROIC) | 18.65% | 18.84% | 8.94% | 8.82% | 12.81% | |||
| Return On Invested Capital Ex Cash (ROICexc) | 20.94% | 25.99% | 10.25% | 10.81% | 14.96% | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | 55.37% | 106.60% | 59.72% | 64.68% | 74.40% | |||
All data in GBP